Overview

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Status:
Active, not recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma following 1-4 lines of prior therapy. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab and are required to be IMiD refractory to be enrolled to the bortezomib regimen, and to not have any prior exposure to daratumumab or other antiCD-38 mAb to be enrolled to the daratumumab regimen.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Oncopeptides AB

Treatments:

Antibodies, Monoclonal
BB 1101
Bortezomib
Daratumumab
Dexamethasone
Dexamethasone acetate
Melphalan